


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	DASANTAFIL
PRONUNCIATION	da san' ta fil
THERAPEUTIC CLAIM	treatment of erectile dysfunction (phosphodiesterase (PDE) 5 isoenzyme inhibitor)
CHEMICAL NAMES	

1. 1*H*-purine-2,6-dione, 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-3,7-dihydro-8-[[*(1R,2R)*-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)
2. 7-(3-bromo-4-methoxybenzyl)-1-ethyl-8-[[*(1R,2R)*-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)-3,7-dihydro-1*H*-purine-2,6-dione

STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>22</sub> H <sub>28</sub> BrN <sub>5</sub> O <sub>5</sub>
MOLECULAR WEIGHT	522.4
TRADEMARK	Unknown as yet
MANUFACTURER	Schering-Plough Corporation
CODE DESIGNATION	SCH 446132
<u>CAS</u> REGISTRY NUMBER	569351-91-3

NOTE: This Statement of Adoption supercedes the Statement of November 26, 2003 for dasantafil (N03;64)